The Latest Cardiac and Vascular News
EMERYVILLE, Calif.–(BUSINESS WIRE)–Fauna Bio, a biotechnology company improving human health by leveraging animal genomics, today announced Faun1083 as its first development candidate. Discovered through Fauna Bio’s proprietary Convergence™ drug discovery platform, Faun1083 is a potential first-in-class therapeutic targeting heart failure with preserved ejection fraction (HFpEF), a disease with currently limited […]
BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently […]
IRVINE, Calif., Jan. 8, 2025 /PRNewswire/ — Relief Cardiovascular, an inQB8 Medical Technologies portfolio company pioneering innovative solutions for the management of heart failure, today announced the closing of a $12M Series A financing. The funding round was co-led by Broadview…
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics Board, through the Clinical Trials Ontario Streamlined Research Ethics Review System, has granted provincial ethics approval for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company’s strategy to address coronary and peripheral disease MARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leading AI-driven health technology company, today announced a collaboration with AliveCor to develop Anumana’s advanced AI algorithms for early cardiac disease detection on AliveCor’s Kardia electrocardiogram (ECG) devices, starting with Anumana’s FDA-cleared algorithm, ECG-AI™ LEF. “This collaboration demonstrates Anumana’s commitment to harnessing the potential of AI to expand […]
DUBLIN–(BUSINESS WIRE)–FIRE1, a leading connected medical device solutions company, today announced the successful completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. “From the beginning, our team has been driven by two core goals: creating […]
January 07, 2025 07:30 AM Eastern Standard Time KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, Inc., (“XyloCor”), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series B financing. New investment will support a randomized, double-blind Phase 2b clinical trial […]
January 07, 2025 07:05 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–AccurKardia, an innovator in ECG-based diagnostics technology, has announced that it has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its ECG-based, AI-powered AK+ Guard™ hyperkalemia detection software. The investigational technology uses Lead I ECG data […]
